Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Naval Daver, MD on Phase 1/2 Trial of DSP-5336 in R/R Acute Leukemia

July 7, 2024
By Naval Daver, MD
Commentary
Video
Conference|European Hematology Association Congress (EHA)

A phase 1/2 trial assessed the use of menin inhibitor DSP-5336 in patients with acute leukemia overexpressing HOXA9 and MEIS1.

CancerNetwork® spoke with Naval G. Daver, MD, professor and director of the Leukemia Research Alliance Program in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, about the clinical implications for the use of DSP-5336 in relapsed/refractory acute leukemia based on findings from a first-in-human phase 1/2 trial (NCT04988555). Investigators of this trial assessed the clinical activity of the menin inhibitor and aimed to determine a recommended phase 2 dose.

Daver highlighted potential development for a larger single-agent phase 2 study assessing the use of DSP-5336 in patients with relapsed/refractory acute leukemia. Although he did not identify a specific target population, he identified a list of menin-sensitive biomarkers that may be included in the next phase such as NPM1 and NUP98.

Among patients with no prior treatment with menin inhibitors and KMT2A rearrangements or NPM1 mutations treated at greater than 140 mg of DSP-5336 twice daily (n = 22), the objective response rate (ORR) was 45%, and the complete response (CR) plus CR with hematologic recovery (CR+CRh) rate was 23%. Across all dose levels (40 mg to 300 mg twice daily) in patients with no prior treatment with menin inhibitors with KMT2A rearrangements or NPM1 mutations, ORR and CR+CRh rate was 32% and 16%, respectively.

Daver presented these findings at the 2024 European Hematology Association (EHA) Congress.

Transcript:

At this time, from a regulatory point and getting these drugs available to patients outside of large academic centers currently running the trials like ours, we're looking at the potential for developing a larger phase 2 single-agent DSP-5336 In relapsed/refractory acute myeloid leukemia [AML]. We haven't decided exactly the target population, but it's probably going to be a mix of different aberrations that are known to upregulate MEIS1 and HOXA9, which are the key biomarkers for menin sensitivity; probably NPM1, KMT2A, NUP98, UBTF, and a few others. That's probably the initial direction: to see if we could produce and reproduce the good CR+CRh [and] overall response rate, while maintaining the very encouraging safety in terms of both differentiation and cardiac issues and see if there's a path to approval in the near future.

[Thinking] more in the long term, [we’re] going to be using combination approaches. We're already looking at starting to develop combinations, both with azacitidine/venetoclax [Venclexta] with DSP-5336. Given the rise of venetoclax as a standard frontline therapy for AML, the question is, “can you add DSP-5336 in patients who have target aberrations like MLL, KMT2A rearrangements, or NPM1, and further improve their response rate, response depth outcome, in combination with FLT3 inhibitors?” We're going to see some of these combinations start hopefully in the next month or 2, and then see if these further boost the response rate, depth of response, durability, and outcome. Personally, I feel that, in the end, the menin inhibitors will have their best use in combinations, ideally, in the frontline setting, where we're going to see not just good response rates and CR+CRh, but actually convert the cure rates from 30% to 35% with HMA-VEN [hypomethylating agents plus venetoclax] at 3 years to potentially up to 50% to 60%. That is really where we want to develop these [combination therapies] in the future.

Reference

Naver D, Erba H, Watts JM, et al. First-in-human phase 1/2 study of the menin-MLL inhibitor DSP-5336 in patients with relapsed or refractory acute leukemia: updated results from dose escalation. Presented at: European Hematologic Association 2024 Hybrid Congress; June 13-16, 2024; Madrid, Spain. Abstract S132.

Recent Videos
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Leadership of a new cancer center as part of JFK University Medical Center discuss how they can support frontline clinicians.
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Related Content
Advertisement

Revumenib Yields Meaningful Benefit in NPM1-Mutated Acute Myeloid Leukemia | Image Credit: © LASZLO - stock.adobe.com.

Revumenib Yields Meaningful Benefit in NPM1-Mutated Acute Myeloid Leukemia

Russ Conroy
May 9th 2025
Article

Phase 2 data support the potential of revumenib to advance the standard of care for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.


Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.

Ensuring Quality Outcomes in Hematologic Cancer Subgroups at EHA 2024

Manali Kamdar, MD;Michael Grunwald, MD;Harry P. Erba, MD, PhD
June 24th 2024
Podcast

Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.


The CHMP Recommends Acalabrutinib Combos for Approval in Untreated CLL

The CHMP Recommends Acalabrutinib Combos for Approval in Untreated CLL

Tim Cortese
April 30th 2025
Article

Results from the phase 3 AMPLIFY trial showed that acalabrutinib plus venetoclax, with or without obinutuzumab, prolonged PFS vs chemoimmunotherapy in CLL.


Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.


A network meta-analysis of 3 clinical trials sought to compare zanubrutinib vs approved BTKis in relapsed/refractory chronic lymphocytic leukemia.

Zanubrutinib Shows Enhanced Efficacy vs Approved BTKis in R/R CLL

Roman Fabbricatore
April 21st 2025
Article

A network meta-analysis of 3 clinical trials sought to compare zanubrutinib vs approved BTKis in relapsed/refractory chronic lymphocytic leukemia.


Tambiciclib was well tolerated in patients with acute myeloid leukemia with myelodysplastic-related changes, and no new safety signals were observed.

Tambiciclib Displays Survival Benefit, Enhanced ORR in AML-MRC

Roman Fabbricatore
April 9th 2025
Article

Tambiciclib was well tolerated in patients with acute myeloid leukemia with myelodysplastic-related changes, and no new safety signals were observed.

Related Content
Advertisement

Revumenib Yields Meaningful Benefit in NPM1-Mutated Acute Myeloid Leukemia | Image Credit: © LASZLO - stock.adobe.com.

Revumenib Yields Meaningful Benefit in NPM1-Mutated Acute Myeloid Leukemia

Russ Conroy
May 9th 2025
Article

Phase 2 data support the potential of revumenib to advance the standard of care for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.


Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.

Ensuring Quality Outcomes in Hematologic Cancer Subgroups at EHA 2024

Manali Kamdar, MD;Michael Grunwald, MD;Harry P. Erba, MD, PhD
June 24th 2024
Podcast

Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.


The CHMP Recommends Acalabrutinib Combos for Approval in Untreated CLL

The CHMP Recommends Acalabrutinib Combos for Approval in Untreated CLL

Tim Cortese
April 30th 2025
Article

Results from the phase 3 AMPLIFY trial showed that acalabrutinib plus venetoclax, with or without obinutuzumab, prolonged PFS vs chemoimmunotherapy in CLL.


Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.


A network meta-analysis of 3 clinical trials sought to compare zanubrutinib vs approved BTKis in relapsed/refractory chronic lymphocytic leukemia.

Zanubrutinib Shows Enhanced Efficacy vs Approved BTKis in R/R CLL

Roman Fabbricatore
April 21st 2025
Article

A network meta-analysis of 3 clinical trials sought to compare zanubrutinib vs approved BTKis in relapsed/refractory chronic lymphocytic leukemia.


Tambiciclib was well tolerated in patients with acute myeloid leukemia with myelodysplastic-related changes, and no new safety signals were observed.

Tambiciclib Displays Survival Benefit, Enhanced ORR in AML-MRC

Roman Fabbricatore
April 9th 2025
Article

Tambiciclib was well tolerated in patients with acute myeloid leukemia with myelodysplastic-related changes, and no new safety signals were observed.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.